pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 29·1 min read
save

Post-Hoc: Lilly gets more secretive and hides Phase 1 pipeline

Eli Lilly is getting more opaque as it gets bigger. Earlier this year, the drugmaker stopped disclosing its early-stage pipeline work. Its Phase 1 projects vanished from the company’s earnings presentation and were pulled from ...

May 29, 2026·read at Endpoints ↗

May 29, 2026 01:23 PM EDTUpdated 19 hours ago R&DPharma Post-Hoc: The world's biggest drug­mak­er gets more se­cre­tive Drew Armstrong Executive Editor Eli Lil­ly is get­ting more opaque as it gets big­ger. Ear­li­er this year, the drug­mak­er stopped dis­clos­ing its ear­ly-stage pipeline work. Its Phase 1 projects … Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
82 words · retrieved Jun 2
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LILLY2ELI LILLY CO

related stories

  • May 6Lilly plans new $4.5B manufacturing investment in IndianaEndpoints
  • May 6Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Canceronclive
  • May 6Novo hikes guidance on Wegovy pill’s fast sales startBioPharma Dive
  • May 6STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share priceSTAT
  • May 4STAT+: French regulator fines Novo and Lilly over weight loss ad campaignsSTAT